Table 2. Combination of hepatic arterial infusion with newer systemic chemotherapy in the second-line treatment of unresectable liver metastases from colorectal cancer.
| Ref. No | Author (year) | No. of Patients | 1st line | 2nd line | RR (%) | Resection rate (%) | Median survival (Months) for all patients |
|---|---|---|---|---|---|---|---|
| (35) | Kemeny (2001) | 46 | 5-FU, IRI | HAI FUDR/Dex SYS IRI |
74 | 8 | 17.2 |
| (36) | Kemeny (2005) | 36 | 5-FU, IRI | HAI FUDR/Dex SYS OXA+IRI; OXA+5-FU/LV |
90 87 |
19.5 | 35.8 22 |
| (41) | Gallagher (2007) | 39 | 5-FU, OXA, IRI | HAI FUDR/Dex SYS IRI |
44 | 18 | 20 |
| (37) | Boige (2008) |
44 | 5-FU, OXA, IRI | HAI OXA SYS 5-FU/LV |
62 | 18 | 16 |
Abbreviations: RR, response rate; 5-FU, 5-fluorouracil; IRI, irinotecan; HAI, hepatic arterial infusion; FUDR, floxuridine; Dex, dexamethasone; SYS, systemic; OXA, oxaliplatin; LV, leucovorin.